文献速递妇科

哌柏西利联合来曲唑治疗雌激素受体阳性晚期/复发性子宫内膜癌:双盲安慰剂对照随机II期ENGOT-EN3/PALEO试验

Palbociclib plus letrozole in estrogen receptor-positive advanced/recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3/PALEO trial.
PubMed 文献 · Gynecol Oncol · 2024-12-09

这项双盲安慰剂对照随机II期筛选试验纳入77例雌激素受体阳性晚期/复发性子宫内膜癌患者,按1:1随机接受来曲唑联合哌柏西利或安慰剂。哌柏西利-来曲唑组中位无进展生存期8.3个月 vs 安慰剂-来曲唑组3.1个月,12个月时PFS风险比0.57(95%CI 0.32-0.99;P=0.044)。3级及以上不良事件哌柏西利-来曲唑组67% vs 安慰剂-来曲唑组30%,最常见为中性粒细胞减少(44% vs 0%)。

要点

  • 哌柏西利-来曲唑组中位PFS 8.3个月 vs 安慰剂-来曲唑组3.1个月。
  • 12个月里程碑分析PFS风险比0.57(95%CI 0.32-0.99;P=0.044)。
  • 3级及以上不良事件哌柏西利-来曲唑组67% vs 安慰剂-来曲唑组30%,中性粒细胞减少44% vs 0%。

核心结论

  • 结果支持哌柏西利-来曲唑联合方案在激素受体阳性晚期/复发性子宫内膜癌中具有潜在治疗作用。
  • 基于这些令人鼓舞的结果,计划开展来曲唑联合CDK4/6抑制剂的III期评估。

研究设计与样本

  • 安慰剂对照双盲随机II期筛选试验(NCT02730429)。
  • 纳入可测量/可评估的雌激素受体阳性子宫内膜样子宫内膜癌,为原发转移或至少接受过1线全身治疗后复发。
  • 按1:1随机,分层因素为既往化疗线数、可测量 vs 可评估不可测量疾病、既往甲羟孕酮/甲地孕酮治疗。
  • 来曲唑2.5 mg口服第1-28天联合哌柏西利125 mg或安慰剂口服第1-21天,每28天重复,直至疾病进展或不可耐受毒性。
  • 2017年2月16日至2018年12月21日随机77例,73例接受治疗(哌柏西利-来曲唑36例,安慰剂-来曲唑37例)。

主要发现

  • 中位随访21.9个月(95%CI 16.7-22.3)。
  • 中位PFS哌柏西利-来曲唑组8.3个月(95%CI 4.6-11.2)vs 安慰剂-来曲唑组3.1个月(95%CI 2.7-6.8)。
  • 12个月里程碑分析PFS风险比0.57(95%CI 0.32-0.99;P=0.044)。
  • 3级及以上不良事件哌柏西利-来曲唑组67% vs 安慰剂-来曲唑组30%。
  • 中性粒细胞减少哌柏西利-来曲唑组44% vs 安慰剂-来曲唑组0%。

临床怎么用

  • 作者认为结果支持哌柏西利-来曲唑联合方案在激素受体阳性晚期/复发性子宫内膜癌中的潜在治疗作用。
  • 作者计划基于这些结果开展来曲唑联合CDK4/6抑制剂的III期评估。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The CDK4/6 inhibitor palbociclib inhibits cyclin A, which is overexpressed in endometrial cancer. Combining palbociclib with endocrine therapy improves efficacy in hormone receptor-positive breast cancer. We investigated palbociclib combined with endocrine therapy for estrogen receptor-positive advanced/recurrent endometrial cancer. PATIENTS AND METHODS: This placebo-controlled double-blind, randomized phase II screening trial (NCT02730429) enrolled women with measurable/evaluable estrogen receptor-positive endometrioid endometrial cancer that was primary metastatic or had relapsed after ≥1 prior systemic therapy. Patients were randomized in a 1:1 ratio, stratified by number of prior chemotherapy lines, measurable versus evaluable non-measurable disease, and prior medroxyprogesterone/megestrol acetate treatment, to receive oral letrozole 2.5 mg on days 1-28 plus either oral palbociclib 125 mg or placebo on days 1-21, repeated every 28 days until disease progression or unacceptable toxicity. The primary end point was investigator-assessed progression-free survival (PFS). RESULTS: Among 77 patients randomized between February 16, 2017, and December 21, 2018, 73 were treated (36 with palbociclib-letrozole, 37 with placebo-letrozole). Median follow-up was 21.9 (95 % CI, 16.7 to 22.3) months. Median PFS was 8.3 (95 % CI, 4.6 to 11.2) versus 3.1 (95 % CI, 2.7 to 6.8) months, respectively. In a landmark analysis at 12 months the PFS hazard ratio was 0.57 (95 % CI, 0.32 to 0.99; P = .044). Grade ≥ 3 adverse events were more common with palbociclib-letrozole (67 %) than placebo-letrozole (30 %), most commonly neutropenia (44 % v 0 %, respectively). CONCLUSION: These results support a potential role of the palbociclib-letrozole combination as treatment for hormone receptor-positive advanced/recurrent endometrial cancer. Based on these encouraging results, phase III evaluation of letrozole combined with a CDK4/6 inhibitor is planned. CLINICAL TRIAL INFORMATION: NCT02730429.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Mirza MR, Bjørge L, Marmé F, et al. Palbociclib plus letrozole in estrogen receptor-positive advanced/recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3/PALEO trial. Gynecol Oncol. 2024. PMID: 39657575. doi:10.1016/j.ygyno.2024.12.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。